

**Experiment Number:** 99032 - 03  
**Test Type:** CHRONIC  
**Route:** SKIN APPLICATION  
**Species/Strain:** RATS/F 344/N

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Pyrogallol  
**CAS Number:** 87-66-1

**Date Report Requested:** 05/30/2012  
**Time Report Requested:** 11:40:45  
**First Dose M/F:** 09/15/04 / 09/16/04  
**Lab:** BAT

F2\_R2

**NTP Study Number:** C99032  
**Lock Date:** 09/07/2007  
**Cage Range:** ALL  
**Date Range:** ALL  
**Reasons For Removal:** ALL  
**Removal Date Range:** ALL  
**Treatment Groups:** Include ALL  
**Study Gender:** Both  
**TDMSE Version:** 2.6.0.0\_007  
**PWG Approval Date:** 12/19/2009

Experiment Number: 99032 - 03

Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: RATS/F 344/N

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pyrogallol

CAS Number: 87-66-1

Date Report Requested: 05/30/2012

Time Report Requested: 11:40:45

First Dose M/F: 09/15/04 / 09/16/04

Lab: BAT

FISCHER 344 RATS MALE

0 MG/KG

5 MG/KG

20 MG/KG

75 MG/KG

## Disposition Summary

Animals Initially In Study	50	50	50	50
Early Deaths				
Moribund Sacrifice	17	14	15	17
Natural Death	10	8	7	5
Survivors				
Natural Death		2		
Terminal Sacrifice	23	26	28	28
Animals Examined Microscopically	50	50	50	50

## ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(50)
Periesophageal Tissue, Hemorrhage	1 (2%)			
Periesophageal Tissue, Inflammation	1 (2%)			
Intestine Large, Cecum	(49)	(50)	(50)	(50)
Inflammation		2 (4%)		
Necrosis		1 (2%)		
Thrombosis		1 (2%)	1 (2%)	
Intestine Large, Colon	(50)	(50)	(50)	(50)
Hyperplasia, Lymphoid		1 (2%)		
Parasite Metazoan	2 (4%)		1 (2%)	6 (12%)
Intestine Large, Rectum	(50)	(50)	(50)	(50)
Parasite Metazoan	4 (8%)	5 (10%)	3 (6%)	4 (8%)
Intestine Small, Duodenum	(50)	(50)	(50)	(50)
Inflammation			1 (2%)	
Ulcer			1 (2%)	
Intestine Small, Ileum	(50)	(50)	(50)	(50)
Inflammation			1 (2%)	
Epithelium, Dysplasia	1 (2%)			
Intestine Small, Jejunum	(50)	(50)	(50)	(50)
Inflammation				1 (2%)
Peyer's Patch, Inflammation, Granulomatous		1 (2%)		
Liver	(50)	(50)	(50)	(50)
Angiectasis	3 (6%)	2 (4%)		1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99032 - 03

Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: RATS/F 344/N

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pyrogallol

CAS Number: 87-66-1

Date Report Requested: 05/30/2012

Time Report Requested: 11:40:45

First Dose M/F: 09/15/04 / 09/16/04

Lab: BAT

FISCHER 344 RATS MALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG
Basophilic Focus	8 (16%)	8 (16%)	11 (22%)	8 (16%)
Clear Cell Focus	18 (36%)	17 (34%)	21 (42%)	21 (42%)
Congestion, Acute	1 (2%)			
Degeneration, Cystic	1 (2%)	6 (12%)	1 (2%)	1 (2%)
Eosinophilic Focus	3 (6%)	2 (4%)		2 (4%)
Fatty Change	1 (2%)	3 (6%)	1 (2%)	3 (6%)
Hematopoietic Cell Proliferation				2 (4%)
Hemorrhage			1 (2%)	
Hepatodiaphragmatic Nodule	3 (6%)	2 (4%)	5 (10%)	4 (8%)
Inflammation	19 (38%)	17 (34%)	17 (34%)	17 (34%)
Mixed Cell Focus	8 (16%)	6 (12%)	6 (12%)	5 (10%)
Bile Duct, Cyst			1 (2%)	
Bile Duct, Hyperplasia	28 (56%)	24 (48%)	27 (54%)	26 (52%)
Centrilobular, Fibrosis	1 (2%)		1 (2%)	
Hepatocyte, Atrophy		1 (2%)	1 (2%)	
Hepatocyte, Degeneration	1 (2%)	1 (2%)		
Hepatocyte, Necrosis	1 (2%)	5 (10%)	4 (8%)	5 (10%)
Hepatocyte, Regeneration	1 (2%)		1 (2%)	
Hepatocyte, Vacuolization Cytoplasmic	19 (38%)	20 (40%)	24 (48%)	18 (36%)
Kupffer Cell, Pigmentation				1 (2%)
Portal, Fibrosis	3 (6%)	6 (12%)	9 (18%)	6 (12%)
Vein, Thrombosis		1 (2%)		
Mesentery	(9)	(2)	(3)	(5)
Necrosis	7 (78%)	2 (100%)	3 (100%)	4 (80%)
Oral Mucosa	(2)	(1)	(4)	(3)
Gingival, Inflammation	2 (100%)	1 (100%)	2 (50%)	3 (100%)
Pharyngeal, Hyperplasia			2 (50%)	
Pancreas	(50)	(50)	(50)	(50)
Acinus, Atrophy	28 (56%)	31 (62%)	28 (56%)	31 (62%)
Acinus, Hyperplasia	3 (6%)	8 (16%)	4 (8%)	1 (2%)
Duct, Cyst	5 (10%)	4 (8%)	3 (6%)	4 (8%)
Salivary Glands	(50)	(50)	(50)	(50)
Hyperplasia		1 (2%)		
Inflammation			1 (2%)	1 (2%)
Duct, Cyst			1 (2%)	
Stomach, Forestomach	(50)	(50)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99032 - 03

Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: RATS/F 344/N

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pyrogallol

CAS Number: 87-66-1

Date Report Requested: 05/30/2012

Time Report Requested: 11:40:45

First Dose M/F: 09/15/04 / 09/16/04

Lab: BAT

FISCHER 344 RATS MALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG
Fibrosis	1 (2%)			
Inflammation	2 (4%)	1 (2%)	1 (2%)	5 (10%)
Perforation		1 (2%)		
Ulcer	4 (8%)	6 (12%)	7 (14%)	4 (8%)
Epithelium, Hyperplasia	2 (4%)	2 (4%)	4 (8%)	6 (12%)
Stomach, Glandular	(50)	(50)	(50)	(50)
Congestion		1 (2%)		
Erosion	2 (4%)	4 (8%)		3 (6%)
Inflammation		4 (8%)		3 (6%)
Ulcer			1 (2%)	
Epithelium, Hyperplasia		2 (4%)	1 (2%)	
Glands, Cyst		1 (2%)	1 (2%)	
Tongue	(1)	(0)	(0)	(2)
Epithelium, Hyperplasia				1 (50%)

## CARDIOVASCULAR SYSTEM

Blood Vessel	(50)	(50)	(50)	(50)
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	46 (92%)	45 (90%)	46 (92%)	47 (94%)
Atrium, Thrombosis		2 (4%)		1 (2%)
Myocardium, Inflammation				1 (2%)
Valve, Thrombosis				1 (2%)
Ventricle, Thrombosis				2 (4%)

## ENDOCRINE SYSTEM

Adrenal Cortex	(50)	(50)	(50)	(50)
Atrophy				1 (2%)
Degeneration, Cystic		1 (2%)	1 (2%)	
Hematopoietic Cell Proliferation			1 (2%)	
Hemorrhage		1 (2%)	1 (2%)	
Hyperplasia	19 (38%)	21 (42%)	29 (58%)	20 (40%)
Hypertrophy	7 (14%)	10 (20%)	10 (20%)	4 (8%)
Mineralization				1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99032 - 03

Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: RATS/F 344/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pyrogallol

CAS Number: 87-66-1

Date Report Requested: 05/30/2012

Time Report Requested: 11:40:45

First Dose M/F: 09/15/04 / 09/16/04

Lab: BAT

---

FISCHER 344 RATS MALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG
Necrosis			1 (2%)	1 (2%)
Vacuolization Cytoplasmic Capsule, Fibrosis, Focal	27 (54%)	18 (36%)	23 (46%)	19 (38%)
Adrenal Medulla	(50)	(50)	(50)	(50)
Angiectasis				1 (2%)
Hemorrhage		1 (2%)		1 (2%)
Hyperplasia	16 (32%)	18 (36%)	20 (40%)	18 (36%)
Infiltration Cellular, Mononuclear Cell				1 (2%)
Mineralization				1 (2%)
Necrosis			1 (2%)	
Islets, Pancreatic	(50)	(50)	(50)	(50)
Hyperplasia				1 (2%)
Parathyroid Gland	(50)	(49)	(47)	(49)
Cyst		1 (2%)		
Hyperplasia		3 (6%)		
Pituitary Gland	(50)	(49)	(50)	(50)
Hemorrhage		1 (2%)		2 (4%)
Pigmentation, Hemosiderin				1 (2%)
Pars Distalis, Atrophy	1 (2%)			3 (6%)
Pars Distalis, Cyst		2 (4%)		4 (8%)
Pars Distalis, Hyperplasia	11 (22%)	10 (20%)	12 (24%)	13 (26%)
Pars Intermedia, Hyperplasia		1 (2%)	1 (2%)	
Thyroid Gland	(50)	(50)	(50)	(50)
Cyst		1 (2%)		
Inflammation				1 (2%)
C-cell, Hyperplasia	18 (36%)	19 (38%)	21 (42%)	18 (36%)

---

GENERAL BODY SYSTEM

None

---

GENITAL SYSTEM

Coagulating Gland	(1)	(0)	(0)	(0)
Epididymis	(50)	(50)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99032 - 03

Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: RATS/F 344/N

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pyrogallol

CAS Number: 87-66-1

Date Report Requested: 05/30/2012

Time Report Requested: 11:40:45

First Dose M/F: 09/15/04 / 09/16/04

Lab: BAT

FISCHER 344 RATS MALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG
Inflammation		1 (2%)	2 (4%)	
Penis	(0)	(0)	(1)	(0)
Congestion			1 (100%)	
Preputial Gland	(50)	(50)	(50)	(50)
Inflammation	2 (4%)	8 (16%)	5 (10%)	7 (14%)
Duct, Hyperplasia, Squamous				1 (2%)
Prostate	(50)	(50)	(50)	(50)
Inflammation	44 (88%)	45 (90%)	48 (96%)	44 (88%)
Epithelium, Hyperplasia	4 (8%)	8 (16%)	5 (10%)	5 (10%)
Epithelium, Metaplasia, Squamous			1 (2%)	1 (2%)
Seminal Vesicle	(50)	(50)	(50)	(50)
Inflammation		1 (2%)		
Bilateral, Atrophy			1 (2%)	
Testes	(50)	(50)	(50)	(50)
Cyst			2 (4%)	1 (2%)
Mineralization			2 (4%)	
Arteriole, Inflammation		1 (2%)		
Bilateral, Germinal Epithelium, Atrophy		3 (6%)		1 (2%)
Germinal Epithelium, Atrophy	5 (10%)	4 (8%)	7 (14%)	9 (18%)
Interstitial Cell, Hyperplasia	11 (22%)	13 (26%)	5 (10%)	8 (16%)

## HEMATOPOIETIC SYSTEM

Bone Marrow	(50)	(50)	(50)	(50)
Hemorrhage		1 (2%)		
Hyperplasia	10 (20%)	11 (22%)	11 (22%)	9 (18%)
Infiltration Cellular, Histiocyte				1 (2%)
Myelofibrosis		1 (2%)	1 (2%)	
Lymph Node	(10)	(8)	(4)	(7)
Degeneration, Cystic			1 (25%)	
Deep Cervical, Degeneration, Cystic		1 (13%)		
Deep Cervical, Hemorrhage				2 (29%)
Mediastinal, Degeneration, Cystic	2 (20%)	1 (13%)		
Mediastinal, Hemorrhage		2 (25%)		
Mediastinal, Hyperplasia		1 (13%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99032 - 03

Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: RATS/F 344/N

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pyrogallol

CAS Number: 87-66-1

Date Report Requested: 05/30/2012

Time Report Requested: 11:40:45

First Dose M/F: 09/15/04 / 09/16/04

Lab: BAT

FISCHER 344 RATS MALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG
Mediastinal, Hyperplasia, Lymphoid		1 (13%)		
Mediastinal, Hyperplasia, Plasma Cell	2 (20%)	1 (13%)	1 (25%)	
Pancreatic, Degeneration, Cystic	1 (10%)			
Lymph Node, Mesenteric	(50)	(50)	(50)	(50)
Degeneration, Cystic		4 (8%)	1 (2%)	5 (10%)
Hemorrhage				2 (4%)
Hyperplasia, Histiocytic			2 (4%)	
Hyperplasia, Plasma Cell			1 (2%)	
Infiltration Cellular, Histiocyte				1 (2%)
Necrosis, Lymphoid		2 (4%)		
Spleen	(50)	(50)	(50)	(50)
Congestion			1 (2%)	
Hematopoietic Cell Proliferation				1 (2%)
Hyperplasia, Lymphoid	3 (6%)	3 (6%)	1 (2%)	2 (4%)
Infarct	2 (4%)	2 (4%)	3 (6%)	1 (2%)
Necrosis, Lymphoid		1 (2%)		
Necrosis, Focal		1 (2%)		
Thrombosis				1 (2%)
Capsule, Fibrosis		1 (2%)		1 (2%)
Capsule, Inflammation				1 (2%)
Lymphoid Follicle, Atrophy		1 (2%)	2 (4%)	
Lymphoid Follicle, Depletion Cellular		1 (2%)		
Thymus	(47)	(48)	(48)	(47)
Cyst			1 (2%)	
Ectopic Parathyroid Gland				1 (2%)
Fibrosis			1 (2%)	
Epithelial Cell, Hyperplasia				1 (2%)

## INTEGUMENTARY SYSTEM

Mammary Gland	(50)	(49)	(50)	(50)
Inflammation		1 (2%)		
Duct, Cyst	1 (2%)			
Duct, Dilatation	1 (2%)			
Skin	(50)	(50)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99032 - 03

Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: RATS/F 344/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pyrogallol

CAS Number: 87-66-1

Date Report Requested: 05/30/2012

Time Report Requested: 11:40:45

First Dose M/F: 09/15/04 / 09/16/04

Lab: BAT

FISCHER 344 RATS MALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG
Abscess		1 (2%)		
Fibrosis				1 (2%)
Hyperkeratosis				1 (2%)
Hyperplasia				2 (4%)
Inflammation				1 (2%)
Ulcer			1 (2%)	1 (2%)
Control, Hyperkeratosis				1 (2%)
Control, Hyperplasia				1 (2%)
Control, Inflammation				1 (2%)
Control, Sebaceous Gland, Hyperplasia				1 (2%)
Sebaceous Gland, Site Of Application, Hyperplasia			12 (24%)	48 (96%)
Site Of Application, Hyperkeratosis		2 (4%)	21 (42%)	48 (96%)
Site Of Application, Hyperplasia		6 (12%)	20 (40%)	50 (100%)
Site Of Application, Inflammation				46 (92%)
Site Of Application, Ulcer				1 (2%)
<hr/>				
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Fibrosis				1 (2%)
Hemorrhage		1 (2%)		
Osteopetrosis				1 (2%)
Epiphysis, Femur, Cyst		1 (2%)		
Mandible, Cyst			1 (2%)	
<hr/>				
NERVOUS SYSTEM				
Brain	(50)	(50)	(50)	(50)
Hemorrhage	3 (6%)	4 (8%)		2 (4%)
Hydrocephalus	2 (4%)	3 (6%)	4 (8%)	
Cerebrum, Inflammation				1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion



Experiment Number: 99032 - 03

Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: RATS/F 344/N

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pyrogallol

CAS Number: 87-66-1

Date Report Requested: 05/30/2012

Time Report Requested: 11:40:45

First Dose M/F: 09/15/04 / 09/16/04

Lab: BAT

FISCHER 344 RATS MALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG
<b>RESPIRATORY SYSTEM</b>				
Lung	(50)	(50)	(50)	(50)
Congestion	1 (2%)		1 (2%)	
Hemorrhage	1 (2%)	3 (6%)		
Hyperplasia			1 (2%)	
Inflammation	6 (12%)	12 (24%)	13 (26%)	8 (16%)
Metaplasia, Squamous			1 (2%)	
Pigmentation, Hemosiderin		1 (2%)		
Thrombosis	2 (4%)	1 (2%)		
Alveolar Epithelium, Hyperplasia	9 (18%)	7 (14%)	10 (20%)	6 (12%)
Alveolus, Infiltration Cellular, Histiocyte	6 (12%)	6 (12%)	5 (10%)	4 (8%)
Bronchiole, Fibrosis			1 (2%)	
Serosa, Hyperplasia	1 (2%)			
Nose	(50)	(50)	(50)	(50)
Inflammation	21 (42%)	28 (56%)	21 (42%)	18 (36%)
Metaplasia, Squamous	1 (2%)			
Polyp, Inflammatory		1 (2%)		
Thrombosis		2 (4%)		
Nasolacrimal Duct, Inflammation				1 (2%)
Trachea	(50)	(50)	(50)	(50)
Infiltration Cellular, Mononuclear Cell		1 (2%)		
Inflammation	1 (2%)		2 (4%)	
Metaplasia, Squamous			1 (2%)	

## SPECIAL SENSES SYSTEM

Eye	(50)	(50)	(50)	(50)
Cataract		2 (4%)		1 (2%)
Anterior Chamber, Inflammation	1 (2%)			
Cornea, Inflammation	1 (2%)			
Retina, Atrophy	1 (2%)	3 (6%)		1 (2%)
Retina, Developmental Malformation			1 (2%)	
Harderian Gland	(50)	(50)	(50)	(50)
Hyperplasia	1 (2%)	1 (2%)	2 (4%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99032 - 03

Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: RATS/F 344/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pyrogallol

CAS Number: 87-66-1

Date Report Requested: 05/30/2012

Time Report Requested: 11:40:45

First Dose M/F: 09/15/04 / 09/16/04

Lab: BAT

---

FISCHER 344 RATS MALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG
Inflammation	1 (2%)	1 (2%)	1 (2%)	2 (4%)
Zymbal's Gland	(1)	(0)	(0)	(0)

---

URINARY SYSTEM

Kidney	(50)	(50)	(50)	(50)
Cyst, Multiple				1 (2%)
Hyperplasia, Tubular			2 (4%)	3 (6%)
Inflammation	1 (2%)	1 (2%)		2 (4%)
Nephropathy	45 (90%)	47 (94%)	49 (98%)	48 (96%)
Thrombosis			1 (2%)	
Pelvis, Calculus Micro Observation Only				1 (2%)
Transitional Epithelium, Hyperplasia				1 (2%)
Urethra	(0)	(0)	(0)	(1)
Bulbourethral Gland, Hyperplasia				1 (100%)
Urinary Bladder	(50)	(50)	(50)	(50)
Hemorrhage				1 (2%)
Inflammation		1 (2%)		
Transitional Epithelium, Hyperplasia			1 (2%)	1 (2%)

---

\*\*\* END OF MALE \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99032 - 03  
 Test Type: CHRONIC  
 Route: SKIN APPLICATION  
 Species/Strain: RATS/F 344/N

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
 Pyrogallol  
 CAS Number: 87-66-1

Date Report Requested: 05/30/2012  
 Time Report Requested: 11:40:45  
 First Dose M/F: 09/15/04 / 09/16/04  
 Lab: BAT

FISCHER 344 RATS FEMALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG
<b>Disposition Summary</b>				
Animals Initially In Study	50	50	50	50
Early Deaths				
Accidentally Killed		1		
Moribund Sacrifice	12	7	18	9
Natural Death	9	9	6	10
Survivors				
Natural Death			1	
Terminal Sacrifice	29	33	25	31
Animals Examined Microscopically	50	50	50	50

**ALIMENTARY SYSTEM**

Esophagus	(50)	(50)	(50)	(50)
Intestine Large, Cecum	(50)	(50)	(50)	(50)
Erosion	1 (2%)			
Inflammation	1 (2%)		1 (2%)	2 (4%)
Thrombosis			1 (2%)	
Ulcer	1 (2%)	1 (2%)	1 (2%)	
Intestine Large, Colon	(50)	(50)	(50)	(50)
Inflammation	1 (2%)			
Parasite Metazoan	2 (4%)	5 (10%)	2 (4%)	1 (2%)
Intestine Large, Rectum	(50)	(50)	(50)	(50)
Parasite Metazoan	3 (6%)	8 (16%)	5 (10%)	5 (10%)
Intestine Small, Duodenum	(50)	(50)	(50)	(50)
Parasite Metazoan	1 (2%)			
Intestine Small, Ileum	(50)	(50)	(50)	(50)
Inflammation		1 (2%)	1 (2%)	
Parasite Metazoan			1 (2%)	
Intestine Small, Jejunum	(50)	(50)	(50)	(50)
Peyer's Patch, Hyperplasia	1 (2%)			
Serosa, Fibrosis	1 (2%)			
Liver	(50)	(50)	(50)	(50)
Angiectasis	1 (2%)	2 (4%)		3 (6%)
Atypia Cellular, Focal			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99032 - 03

Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: RATS/F 344/N

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pyrogallol

CAS Number: 87-66-1

Date Report Requested: 05/30/2012

Time Report Requested: 11:40:45

First Dose M/F: 09/15/04 / 09/16/04

Lab: BAT

FISCHER 344 RATS FEMALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG
Basophilic Focus	31 (62%)	34 (68%)	28 (56%)	34 (68%)
Clear Cell Focus	9 (18%)	1 (2%)	2 (4%)	4 (8%)
Congestion, Diffuse				1 (2%)
Degeneration, Cystic		1 (2%)	1 (2%)	
Eosinophilic Focus	2 (4%)	4 (8%)	2 (4%)	1 (2%)
Fatty Change	4 (8%)	1 (2%)	6 (12%)	4 (8%)
Hematopoietic Cell Proliferation		1 (2%)		
Hemorrhage			1 (2%)	1 (2%)
Hepatodiaphragmatic Nodule	1 (2%)	6 (12%)	3 (6%)	7 (14%)
Inflammation	23 (46%)	26 (52%)	10 (20%)	16 (32%)
Mixed Cell Focus	5 (10%)	5 (10%)	3 (6%)	4 (8%)
Bile Duct, Hyperplasia	10 (20%)	7 (14%)	7 (14%)	7 (14%)
Hepatocyte, Hypertrophy		1 (2%)		
Hepatocyte, Necrosis	1 (2%)	1 (2%)	3 (6%)	
Hepatocyte, Regeneration			1 (2%)	1 (2%)
Hepatocyte, Vacuolization Cytoplasmic	12 (24%)	15 (30%)	8 (16%)	6 (12%)
Hepatocyte, Midzonal, Degeneration	1 (2%)			
Portal, Fibrosis	4 (8%)	1 (2%)	3 (6%)	1 (2%)
Serosa, Fibrosis				1 (2%)
Mesentery	(8)	(11)	(13)	(10)
Necrosis	6 (75%)	11 (100%)	13 (100%)	10 (100%)
Oral Mucosa	(2)	(2)	(0)	(0)
Gingival, Cyst	1 (50%)	1 (50%)		
Gingival, Inflammation	1 (50%)	1 (50%)		
Pancreas	(50)	(50)	(50)	(50)
Basophilic Focus		1 (2%)		
Acinus, Atrophy	16 (32%)	13 (26%)	17 (34%)	15 (30%)
Acinus, Hyperplasia	3 (6%)	8 (16%)	1 (2%)	5 (10%)
Duct, Cyst	4 (8%)	2 (4%)	2 (4%)	2 (4%)
Salivary Glands	(50)	(50)	(50)	(50)
Hyperplasia			1 (2%)	
Inflammation			1 (2%)	
Mineralization			1 (2%)	
Stomach, Forestomach	(50)	(50)	(50)	(50)
Inflammation	1 (2%)		2 (4%)	3 (6%)
Ulcer	5 (10%)	3 (6%)	7 (14%)	3 (6%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99032 - 03

Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: RATS/F 344/N

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pyrogallol

CAS Number: 87-66-1

Date Report Requested: 05/30/2012

Time Report Requested: 11:40:45

First Dose M/F: 09/15/04 / 09/16/04

Lab: BAT

FISCHER 344 RATS FEMALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG
Epithelium, Hyperplasia	3 (6%)		1 (2%)	3 (6%)
Stomach, Glandular	(50)	(50)	(50)	(50)
Erosion	1 (2%)	1 (2%)	1 (2%)	
Inflammation	2 (4%)		1 (2%)	2 (4%)
Ulcer			1 (2%)	
Epithelium, Cyst				1 (2%)

## CARDIOVASCULAR SYSTEM

Blood Vessel	(50)	(50)	(50)	(50)
Thrombosis			1 (2%)	
Heart	(50)	(50)	(50)	(50)
Cardiomyopathy	44 (88%)	45 (90%)	46 (92%)	45 (90%)
Inflammation	1 (2%)			
Atrium, Thrombosis	1 (2%)	1 (2%)	1 (2%)	
Myocardium, Inflammation		1 (2%)		

## ENDOCRINE SYSTEM

Adrenal Cortex	(50)	(50)	(50)	(50)
Angiectasis			1 (2%)	
Atrophy			1 (2%)	1 (2%)
Atypia Cellular			1 (2%)	
Degeneration, Cystic	8 (16%)	4 (8%)	4 (8%)	2 (4%)
Hematopoietic Cell Proliferation	1 (2%)			1 (2%)
Hemorrhage				2 (4%)
Hyperplasia	29 (58%)	24 (48%)	26 (52%)	29 (58%)
Hypertrophy	17 (34%)	15 (30%)	24 (48%)	21 (42%)
Necrosis			1 (2%)	
Thrombosis			1 (2%)	
Vacuolization Cytoplasmic	14 (28%)	13 (26%)	13 (26%)	18 (36%)
Adrenal Medulla	(50)	(50)	(50)	(50)
Hyperplasia	5 (10%)	1 (2%)	6 (12%)	4 (8%)
Infiltration Cellular, Mononuclear Cell				1 (2%)
Islets, Pancreatic	(50)	(50)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99032 - 03

Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: RATS/F 344/N

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pyrogallol

CAS Number: 87-66-1

Date Report Requested: 05/30/2012

Time Report Requested: 11:40:45

First Dose M/F: 09/15/04 / 09/16/04

Lab: BAT

FISCHER 344 RATS FEMALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG
Parathyroid Gland	(49)	(49)	(50)	(49)
Hyperplasia			2 (4%)	
Pituitary Gland	(50)	(50)	(50)	(50)
Angiectasis			1 (2%)	
Cyst			1 (2%)	1 (2%)
Hemorrhage	1 (2%)			2 (4%)
Pars Distalis, Cyst	4 (8%)	8 (16%)	7 (14%)	7 (14%)
Pars Distalis, Hyperplasia	19 (38%)	16 (32%)	17 (34%)	19 (38%)
Pars Distalis, Inflammation		1 (2%)		
Thyroid Gland	(50)	(50)	(50)	(50)
Cyst				1 (2%)
C-cell, Hyperplasia	22 (44%)	31 (62%)	23 (46%)	31 (62%)
Follicle, Cyst		1 (2%)		
Follicular Cell, Hyperplasia				1 (2%)

## GENERAL BODY SYSTEM

None

## GENITAL SYSTEM

Clitoral Gland	(50)	(50)	(50)	(50)
Atrophy			1 (2%)	
Fibrosis			1 (2%)	
Hyperplasia	3 (6%)	1 (2%)	4 (8%)	1 (2%)
Inflammation	3 (6%)	4 (8%)	6 (12%)	6 (12%)
Duct, Dilatation	1 (2%)		2 (4%)	
Ovary	(50)	(50)	(50)	(50)
Cyst	3 (6%)	3 (6%)	6 (12%)	1 (2%)
Uterus	(50)	(50)	(50)	(50)
Hemorrhage		1 (2%)		
Hyperplasia, Adenomatous				1 (2%)
Inflammation	3 (6%)			1 (2%)
Cervix, Fibrosis	1 (2%)			
Endometrium, Cyst			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99032 - 03

Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: RATS/F 344/N

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pyrogallol

CAS Number: 87-66-1

Date Report Requested: 05/30/2012

Time Report Requested: 11:40:45

First Dose M/F: 09/15/04 / 09/16/04

Lab: BAT

FISCHER 344 RATS FEMALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG
Endometrium, Edema			1 (2%)	
Endometrium, Hyperplasia, Cystic	5 (10%)	5 (10%)	4 (8%)	
Vagina	(0)	(1)	(0)	(0)
Inflammation		1 (100%)		

## HEMATOPOIETIC SYSTEM

Bone Marrow	(50)	(50)	(50)	(50)
Fibrosis	1 (2%)			
Hyperplasia	10 (20%)	6 (12%)	10 (20%)	10 (20%)
Myelofibrosis			2 (4%)	1 (2%)
Lymph Node	(3)	(2)	(4)	(2)
Hemorrhage			1 (25%)	
Deep Cervical, Hyperplasia, Plasma Cell	1 (33%)			
Mediastinal, Congestion		1 (50%)		
Mediastinal, Hemorrhage	2 (67%)		1 (25%)	
Mediastinal, Hyperplasia, Plasma Cell	1 (33%)	1 (50%)	1 (25%)	
Pancreatic, Hemorrhage			1 (25%)	
Lymph Node, Mesenteric	(50)	(50)	(50)	(50)
Degeneration, Cystic	3 (6%)			1 (2%)
Hyperplasia, Lymphoid				1 (2%)
Hyperplasia, Plasma Cell			1 (2%)	1 (2%)
Infiltration Cellular, Histiocyte		1 (2%)		
Inflammation		2 (4%)		
Spleen	(50)	(50)	(50)	(50)
Accessory Spleen			1 (2%)	1 (2%)
Hematopoietic Cell Proliferation		3 (6%)	1 (2%)	
Hyperplasia, Lymphoid		1 (2%)	1 (2%)	2 (4%)
Infarct		2 (4%)	4 (8%)	1 (2%)
Pigmentation, Hemosiderin		1 (2%)		1 (2%)
Capsule, Hyperplasia			1 (2%)	
Capsule, Inflammation			1 (2%)	
Lymphoid Follicle, Atrophy		1 (2%)	1 (2%)	1 (2%)
Thymus	(50)	(50)	(49)	(50)
Cyst				1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99032 - 03

Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: RATS/F 344/N

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pyrogallol

CAS Number: 87-66-1

Date Report Requested: 05/30/2012

Time Report Requested: 11:40:45

First Dose M/F: 09/15/04 / 09/16/04

Lab: BAT

FISCHER 344 RATS FEMALE

0 MG/KG

5 MG/KG

20 MG/KG

75 MG/KG

INTEGUMENTARY SYSTEM

Mammary Gland	(50)	(50)	(50)	(50)
Inflammation	1 (2%)	4 (8%)		1 (2%)
Duct, Cyst	1 (2%)	1 (2%)	1 (2%)	5 (10%)
Duct, Hyperplasia, Cystic	1 (2%)			
Skin	(50)	(50)	(50)	(50)
Hyperkeratosis		2 (4%)		
Hyperplasia				1 (2%)
Ulcer				1 (2%)
Control, Hyperplasia			1 (2%)	
Control, Inflammation			1 (2%)	
Sebaceous Gland, Site Of Application, Hyperplasia			5 (10%)	41 (82%)
Site Of Application, Hyperkeratosis		6 (12%)	23 (46%)	49 (98%)
Site Of Application, Hyperplasia		9 (18%)	11 (22%)	49 (98%)
Site Of Application, Inflammation		3 (6%)	6 (12%)	49 (98%)

MUSCULOSKELETAL SYSTEM

Bone	(50)	(50)	(50)	(50)
Osteopetrosis			1 (2%)	
Osteosclerosis	1 (2%)			
Fibula, Tibia, Fracture	1 (2%)			
Skeletal Muscle	(0)	(0)	(2)	(0)

NERVOUS SYSTEM

Brain	(50)	(50)	(50)	(50)
Hemorrhage	1 (2%)	1 (2%)		1 (2%)
Hydrocephalus	1 (2%)	3 (6%)	3 (6%)	3 (6%)
Thrombosis			1 (2%)	
Cerebellum, Gliosis	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion



Experiment Number: 99032 - 03

Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: RATS/F 344/N

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pyrogallol

CAS Number: 87-66-1

Date Report Requested: 05/30/2012

Time Report Requested: 11:40:45

First Dose M/F: 09/15/04 / 09/16/04

Lab: BAT

FISCHER 344 RATS FEMALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG
Cerebrum, Necrosis	1 (2%)			
Peripheral Nerve	(0)	(0)	(1)	(0)
Spinal Cord	(0)	(0)	(1)	(0)

## RESPIRATORY SYSTEM

Larynx	(0)	(1)	(0)	(0)
Foreign Body		1 (100%)		
Inflammation		1 (100%)		
Lung	(50)	(50)	(50)	(50)
Congestion		1 (2%)	1 (2%)	1 (2%)
Fibrosis	2 (4%)			
Hemorrhage		2 (4%)		
Inflammation	8 (16%)	9 (18%)	2 (4%)	10 (20%)
Thrombosis	1 (2%)			
Alveolar Epithelium, Hyperplasia	6 (12%)	11 (22%)	5 (10%)	12 (24%)
Alveolus, Infiltration Cellular, Histiocyte	2 (4%)	3 (6%)	2 (4%)	6 (12%)
Alveolus, Pigmentation, Hemoglobin				1 (2%)
Bronchiole, Hyperplasia				1 (2%)
Serosa, Fibrosis		1 (2%)		
Nose	(50)	(50)	(50)	(50)
Inflammation	11 (22%)	10 (20%)	12 (24%)	8 (16%)
Metaplasia, Squamous	1 (2%)	1 (2%)		
Thrombosis	1 (2%)	1 (2%)	1 (2%)	
Goblet Cell, Hyperplasia	2 (4%)	2 (4%)		
Nasolacrimal Duct, Inflammation		1 (2%)		
Nasolacrimal Duct, Squamous Epithelium, Hyperplasia	1 (2%)			
Nasopharyngeal Duct, Inflammation			2 (4%)	
Olfactory Epithelium, Hyperplasia			1 (2%)	
Respiratory Epithelium, Necrosis		1 (2%)		
Squamous Epithelium, Necrosis		1 (2%)		
Vomeronasal Organ, Necrosis		1 (2%)		
Trachea	(50)	(50)	(50)	(50)
Infiltration Cellular, Mononuclear Cell	1 (2%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 99032 - 03

Test Type: CHRONIC

Route: SKIN APPLICATION

Species/Strain: RATS/F 344/N

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Pyrogallol

CAS Number: 87-66-1

Date Report Requested: 05/30/2012

Time Report Requested: 11:40:45

First Dose M/F: 09/15/04 / 09/16/04

Lab: BAT

FISCHER 344 RATS FEMALE	0 MG/KG	5 MG/KG	20 MG/KG	75 MG/KG
Inflammation	1 (2%)		1 (2%)	

## SPECIAL SENSES SYSTEM

Eye	(50)	(50)	(50)	(50)
Cataract	3 (6%)	4 (8%)	1 (2%)	1 (2%)
Synechia	1 (2%)	1 (2%)		
Anterior Chamber, Exudate				1 (2%)
Bilateral, Retina, Atrophy		1 (2%)		
Optic Nerve, Atrophy	1 (2%)		1 (2%)	
Posterior Chamber, Exudate				1 (2%)
Retina, Atrophy	3 (6%)	3 (6%)	2 (4%)	
Retina, Developmental Malformation	1 (2%)			
Retina, Dysplasia		1 (2%)		1 (2%)
Harderian Gland	(50)	(50)	(50)	(50)
Hyperplasia	1 (2%)	2 (4%)	4 (8%)	3 (6%)
Inflammation	2 (4%)	4 (8%)		4 (8%)
Metaplasia, Squamous	1 (2%)			
Pigmentation, Porphyrin		3 (6%)	6 (12%)	1 (2%)

## URINARY SYSTEM

Kidney	(50)	(50)	(50)	(50)
Accumulation, Hyaline Droplet		2 (4%)		
Atrophy			1 (2%)	
Cyst		1 (2%)	1 (2%)	
Hypertrophy			1 (2%)	
Infiltration Cellular, Lipocyte		1 (2%)		
Inflammation	1 (2%)		3 (6%)	
Nephropathy	46 (92%)	42 (84%)	42 (84%)	44 (88%)
Papilla, Necrosis			1 (2%)	
Transitional Epithelium, Hyperplasia			1 (2%)	
Urinary Bladder	(50)	(50)	(50)	(49)
Transitional Epithelium, Hyperplasia		1 (2%)	1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 99032 - 03

**Test Type:** CHRONIC

**Route:** SKIN APPLICATION

**Species/Strain:** RATS/F 344/N

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Pyrogallol

**CAS Number:** 87-66-1

**Date Report Requested:** 05/30/2012

**Time Report Requested:** 11:40:45

**First Dose M/F:** 09/15/04 / 09/16/04

**Lab:** BAT

---

**FISCHER 344 RATS FEMALE**

**0 MG/KG**

**5 MG/KG**

**20 MG/KG**

**75 MG/KG**

---

\*\*\* END OF REPORT \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion